◼ Archived
Business
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
Novartis faces a multi-billion dollar financial hit from clinical trial setbacks yet maintains financial guidance.
Avidity
4 trends tracked about this subject — the full history, oldest to newest below.
◼ Archived
Business
🔮 fades ✗
Novartis Stock Tanks Following Third Major Pipeline Setback
Novartis stock experiences a sharp decline following a Phase 3 failure for a dystrophy drug linked to its $12 billion Avidity acquisition.
◼ Archived
Business
🔮 fades ✓
Novartis stock slides as centerpiece of $12B Avidity buyout flunks ‘crucial’ phase 3 test
Novartis shares experienced their worst single-day drop in over two decades following the failure of a crucial phase 3 trial for an Avidity buyout drug.
◼ Archived
Business
🔮 fades ✗
Novartis’s Latest Trial Setback Sinks Stock
Novartis shares drop significantly following multiple trial setbacks and difficult dealmaking in the pharmaceutical sector.